Loading...
•
Jun 30, 2022
Reviva Q2 2022 Earnings Report
Reviva reported financial results for the second quarter ended June 30, 2022 and summarized recent business highlights.
Key Takeaways
Reviva Pharmaceuticals reported a net loss of $5.3 million for the second quarter of 2022, with cash totaling $19.4 million as of June 30, 2022. The company is focused on advancing the clinical development of brilaroxazine in the Phase 3 RECOVER study for schizophrenia.
Enrollment is on pace for the ongoing pivotal Phase 3 RECOVER trial.
Topline data for RECOVER evaluating brilaroxazine for schizophrenia is expected in mid-2023.
Cash totaled $19.4 million as of June 30, 2022.
Over 20% of the approximately 400 patients planned already enrolled.
Forward Guidance
Reviva believes that based on the current operating plan and financial resources, the Company’s cash as of June 30, 2022 will be sufficient to fund its current operating plans through at least March 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...